Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — H1 2022 Earnings Presentation
23 slides from Hyphens Pharma International's earnings presentation, Aug 17, 2022
Slide 1: General Announcement: Results Briefing 1H 2022
8/17/22, 12:25 PM General Announcement::RESULTS BRIEFING 1H 2022 GENERAL ANNOUNCEMENT::RESULTS BRIEFING 1H 2022 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement T
Slide 2: Results Briefing 1H 2022
HYPHENS PHARMA INTERNATIONAL LIMITED Results Briefing 1H 2022 17 AUG 2022
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Financial Results
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 5: 1.1 Financial Performance
1.1 FINANCIAL PERFORMANCE Revenue (S$’m) Profit After Tax (S$’m) 80.7 6.2 61.5 60.4 60.6 63.8 62.1 54.8 4.2 3.5 3.4 3.1 2.5 1.0 * Excl JSS
Slide 6: 1.2 Financial Performance (Without Novem)
1.2 FINANCIAL PERFORMANCE (WITHOUT NOVEM) Revenue (S$’m) Profit After Tax (S$’m) 71.5 4.8 61.5 60.6 63.8 60.8 4.2 60.4 54.8 3.5 3.4 3.1 2.4 1.0 † † † † * Excl JSS † Excludes Novem Revenue and Profit (acquired in Dec 2021)
Slide 7: 1.3 EBITDA Over the Years
1.3 EBITDA OVER THE YEARS 10,130 10,555 8,953 9,299 9,237 * * Exclude goodwill impairment
Slide 8: 1.4 Income Statement
1.4 INCOME STATEMENT 1H2022 1H2021 YoY 1H2022 vs 1H2021 S$000 S$000 % • Revenue increased across all business Revenue 80,704 63,807 26.5% segments and most geographical Cost of sales (49,627) (39,055) 27.1% locations. Novem contributed $9.2mil in revenue; Hyphens organic growth at 12%. Gross profit
Slide 9: 1.5 Revenue by Business Segments
1.5 REVENUE BY BUSINESS SEGMENTS 80.0 70.0 60.0 60% Revenue S$'mil 50.0 50% 52% 52% 52% 55% 40.0 51% 30.0 15% 15% 16% 13% 13% 12% 15% 20.0 10.0 36% 33% 35% 33% 33% 32% 27% - 1H2019 2H2019 1H2020 2H2020 1H2021 2H2021 1H2022 Specialty 28.2 33.8 30.2 31.8 33.3 32.3 48.2 Proprietary 7.1 7.4 9.1 9.0 9.3
Slide 10: 1.6 EBITDA Margin by Business Segments
1.6 EBITDA MARGIN BY BUSINESS SEGMENTS 14.3% 12.4% 12.6% 12.4% 9.9% 9.7% 9.5% 8.5% 7.0% Notes: 4.0% 3.6% Due to restatement of 2.8% revenue in prior years to be consistent with FY2021, prior years’ EBITDA margins have been updated accordingly. Specialty pharma principals Proprietary brands Medical h
Slide 11: Financial Position
2 FINANCIAL POSITION S$’000 30 Jun 2022 31 Dec 2021 Total assets 104,459 99,191 Inventories 20,700 25,290 Trade & other receivables 30,565 28,722 Cash & cash equivalents 28,444 19,461 Total liabilities 39,452 44,455 Trade & other payables 30,678 33,563 Bank borrowings 3,661 6,075 Total equity 65,007
Slide 12: Cashflow Statement
3 CASHFLOW STATEMENT S$'000 1H2022 1H2021 Cashflow from operating activities Profit before tax 7,830 5,230 Adjustments for non-cash/non-op items 1,267 1,056 Changes in working capital (50) 1,003 Tax paid (842) (1,023) Cashflow from operating activities 8,205 6,266 Cashflow used in investing activiti
Slide 13: Key Contributions to the Performance
KEY CONTRIBUTIONS TO THE PERFORMANCE 1. Post-COVID recover: - Our major market of Singapore, Malaysia and Vietnam registered positive and double digit improvement in sales performance. 2. Additional of Novem to the Group. - Contributed positively to both top and bottom line.
Slide 14: Business Updates
LA e wo > Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 15: Successfully Raised S$6M for Subsidiary Docmed
SUCCESSFULLY RAISED S$6M FOR OUR SUBSIDIARY DOCMED VALUING DOCMED AT S$60M
Slide 16: Successful Registration & Launch of Ocean Health Products Outside Singapore
SUCCESSFUL REGISTRATION & LAUNCH OF OCEAN HEALTH PRODUCTS OUTSIDE OF SINGAPORE LAUNCHED! PREPARING TO LAUNCH Vietnam PREPARING TO LAUNCH LAUNCHED! PREPARINGTO LAUNCH Malaysia (JUST APPROVED) Indonesia
Slide 17: Project Symphony
People, Organisation & Culture Project Symphony “ Clearly stipulate vision/core values that genuinely represent our current behaviour and aspirations. The process will gel and energize us as a team to enable us to become winners in the market competition. ”
Slide 18: Licensed Lederlon
LICENSED LEDERLON® An Exclusive License & Supply agreement for 10 years from date of signature with auto-renewal. An intra-articular corticosteroid that is different from currently registered product, for the treatment of osteo- arthritis. Licensed from Esteve Group, a mid size European specialty ph
Slide 19: Cessation of Distributorship with Biosensors Interventional
CESSATION OF DISTRIBUTORSHIP WITH BIOSENSORS INTERVENTIONAL • Agreement will lapse by end of 2022. • Agreement ended amicably. • Contributed to 3% of revenue in FY 21. • Contributed to 6% of revenue in 1H 22. • Contributed to 12% of revenue in FY 17.
Slide 20: Business Outlook
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 21: Investing for Growth
INVESTING FOR GROWTH 1. Investment in Proprietary Brands 2. Internationalisation 3. Going Digital Docmed is expected to speed up hiring and deployment of the fund raised. 4. Strengthen Specialty Pharma Portfolio 5. Acquisitions
Slide 22: Questions & Answers
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 23: Hyphens Pharma International Limited contact details
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — H1 2022 Earnings Presentation on 6ix